v3.25.1

Related parties (Tables)

12 Months Ended

Dec. 31, 2024

Related parties

Summary of transactions with related party

​

​	​	​	​	​	​	​	​	​	​
​	​	December 31,
​	​	2024			2023		​	2022
​	​	(Euro, in thousands)
​	​	​	​	​	​	​	​	​	​
Trade and other receivables (1)	​	€	2,268	​	€	5,198	​	€	7,877
Trade and other payables	​	​	—	​	​	585	​	​	​
​	​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​	​	2024			2023		​	2022
​	​	(Euro, in thousands)
​	​	​	​	​	​	​	​	​	​
Revenues recognized related to the performance obligation for the drug discovery platform	​	€	230,182	​	€	230,242	​	€	230,423
Revenues recognized related to the filgotinib performance obligation (2)	​	​	26,041	​	​	429,439	​	​	174,432
Royalty income related to the commercialization of filgotinib	​	​	10,604	​	​	9,466	​	​	10,726
Cost reimbursements related to the development of GLPG1690 (3)	​	​	128	​	​	299	​	​	411
Cross charges from and to Gilead relating to filgotinib (4)	​	​	—	​	​	3,643	​	​	(2,374)
Costs (-)/deduction of costs relating to our 50/50 profit/(cost) share mechanism (5)	​	​	​	​	​	​	​	​	​
included in sales and marketing expenses	​	​	—	​	​	—	​	​	31
included in research and development expenditure	​	​	—	​	​	—	​	​	(31)
Purchase of raw materials, semi-finished products and finished products of Jyseleca	​	€	—	​	€	—	​	€	13,539

Summary of remuneration package of the members of key management personnel

​

​	​	​	​	​	​	​	​	​	​
​	​	Year ended December 31,
​		2024			2023			2022
Remuneration of key management personnel:	​	​		​	​		​	​
Euro, in thousands (except for the number of subscription rights and RSUs)	​	​	​	​	​	​	​	​	​
Short-term benefits to executive Committee members as a group (1)	​	€	3,279	​	€	3,902	​	€	3,444
Board fees for members of the Board of Directors	​	​	859	​	​	749	​	​	740
Post-employment benefits (2)	​	​	186	​	​	209	​	​	240
Severance package (3)	​	​	—	​	​	3,150	​	​	—
Subscription rights granted in the year	​	​	​	​	​	​	​	​	​
Number of subscription rights granted in the year to Executive Committee members as a group	​	​	185,000	​	​	325,000	​	​	1,124,000
Total cost of subscription rights granted in the year under IFRS 2	​	€	1,765	​	€	5,163	​	€	27,010
Number of RSUs granted in the year	​	​	​	​	​	​	​	​	​
Total number of RSUs granted in the year to Executive Committee members as a group (1)(4)	​	​	299,516	​	​	331,066	​	​	200,478

X

- Definition

The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [domain]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 24
-IssueDate 2024-01-01
-Paragraph 18A
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18A&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 24
-IssueDate 2024-01-01
-Paragraph 18
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_RelatedPartyTransactionsAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration